Citigroup’s Mereo BioPharma MREO Stock Holding History

Citigroup’s Portfolio MREO Stock Details MREO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$17	Buy	+52	New	+$16	﹤0.01%	5582
2026 Q1	–	Sell	-195,814	Closed	-$81.6K	–	6221
2025 Q4	$81.6K	Buy	+195,814	New	+$373K	﹤0.01%	4406
2023 Q2	–	Sell	-1,130,650	Closed	-$799K	–	5673
2023 Q1	$799K	Buy	1,130,650 +1,129,103	+72,987%	+$1.02M	﹤0.01%	2740
2022 Q4	$1.16K	Sell	1,547 -17,368	-92%	-$14.3K	﹤0.01%	5369
2022 Q3	$16K	Buy	18,915 +17,044	+911%	+$20.9K	﹤0.01%	4819
2022 Q2	$2K	Sell	1,871 -647	-26%	-$501	﹤0.01%	5900
2022 Q1	$3K	Sell	2,518 -857	-25%	-$1.11K	﹤0.01%	5965
2021 Q4	$5K	Buy	+3,375	New	+$6.75K	﹤0.01%	5661

Other funds holding MREO

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

DCM

Defilade Capital Management Emeryville, California $747M AUM

Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Citigroup's MREO Position: Q2 2026 in Review

Citigroup opened a new position in Mereo BioPharma (MREO) in Q2 2026: 52 shares worth $17. The stake represents ﹤0.01% of the portfolio and ranks #5582 among its holdings. This is a return to the name: Citigroup previously reported a position in MREO as recently as Q4 2025.

Citigroup first reported a position in MREO in Q4 2021 and has held it in 8 quarters since. The position peaked at $799K in Q1 2023. 61 funds tracked by Wall St. Rank hold MREO as of Q2 2026.

Citigroup held 52 shares of Mereo BioPharma worth $17 as of Q2 2026.
Mereo BioPharma was a new Citigroup position in Q2 2026.
Mereo BioPharma made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #5582 holding.
Citigroup first reported a position in Mereo BioPharma in Q4 2021 and has held it in 8 quarters since.
Citigroup's Mereo BioPharma position peaked at $799K in Q1 2023.
61 funds tracked by Wall St. Rank held Mereo BioPharma as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.